Review Articles
Vol. 2 No. 2 (2010): New Drugs and Hemopoietic Stem Cell Transplantation in Oncohematological Diseases of the Elderly
ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: July 19, 2010
2327
Views
536
Downloads
1157
HTML
Hematology,
Blood and Marrow Transplantation
Authors
Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndromes (MDS). Most patients with MDS are older than 60 years and age-associated morbidities limit the patients’ options for curative transplant therapy. Since the development of conditioning regimens with reduced toxicity, the age limitations for HCT have waned for those patients with good performance status. This review will discuss the role of HCT for MDS based on prognostic features, the optimal timing of HCT, and outcomes based on patient age.
Downloads
Download data is not yet available.
Citations
Ethics Approval
Review ArticleHow to Cite
“ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME” (2010) Mediterranean Journal of Hematology and Infectious Diseases, 2(2), p. e2010019. doi:10.4084/mjhid.2010.019.
